Ramucirumab

證據等級: L5

預測適應症: 10 個

Ramucirumab: Drug Repurposing Assessment — Insufficient Data for Full Evaluation

One-Sentence Summary

Ramucirumab is a fully human IgG1 monoclonal antibody targeting VEGFR-2, developed as an antineoplastic agent for gastric/GEJ adenocarcinoma, NSCLC, and colorectal cancer. The current Evidence Pack contains no TxGNN-predicted new indications, and Germany market authorization records were not retrieved (0 licenses on file). A complete repurposing evaluation cannot be performed at this stage; this report documents available findings and the data gaps that must be resolved before proceeding.

Quick Overview

Item	Content
Original Indication	Not specified in Evidence Pack
Predicted New Indication	None — TxGNN predictions not available
TxGNN Prediction Score	Not available
Evidence Level	Not assessable
Germany Market Status	Not marketed (0 authorizations on file)
Number of Authorizations	0
Recommended Decision	Hold

Mechanism of Action

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known pharmacological information, Ramucirumab is a fully human IgG1 monoclonal antibody that selectively binds to the extracellular domain of VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2), blocking the binding of VEGF-A, VEGF-C, and VEGF-D ligands and their downstream pro-angiogenic signaling cascades.

Its antitumour efficacy in gastric and gastroesophageal junction adenocarcinoma has been established in pivotal Phase 3 trials (REGARD, RAINBOW). By targeting tumour vasculature rather than cancer cells directly, the mechanism is theoretically applicable to any solid tumour with significant VEGFR-2-dependent angiogenesis — a rationale that has already supported approval extensions to NSCLC, colorectal cancer, and hepatocellular carcinoma in multiple jurisdictions.

Once TxGNN prediction data becomes available, mechanism-disease alignment can be formally evaluated.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — Anti-VEGFR2 monoclonal antibody (antiangiogenic)
Myelosuppression Risk	Low to moderate (neutropenia has been reported; considerably less severe than conventional cytotoxic chemotherapy)
Emetogenicity Classification	Low
Monitoring Items	Blood pressure (hypertension is a class effect of anti-VEGF agents), urinalysis for proteinuria, CBC with differential, hepatic function, wound healing status
Handling Protection	Standard biologic handling protocols apply; not classified as a conventional cytotoxic agent requiring cytotoxic spill kits or HEPA-protected preparation areas

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is missing all three prerequisites for a repurposing evaluation — TxGNN prediction output, safety/contraindication data, and Germany market authorization records — making it impossible to assess either therapeutic opportunity or risk profile at this time.

To proceed, the following is needed:

TxGNN predictions (predicted_indications) must be generated for Ramucirumab before any indication assessment can begin
Package insert warnings and contraindications — TFDA PDF parsing was logged as successful (query 4) but no data was returned; this must be resolved
Drug interaction data — DDI query returned not_found; a broader database search (e.g., DrugBank, Lexicomp) is recommended
Germany BfArM/EMA authorization check — Ramucirumab may hold EMA marketing authorisation that was not captured in this query; a direct EMA product database lookup is advised to confirm actual market status before classifying as "not marketed"
MOA data from DrugBank — DrugBank query returned 1 result (query 3) but original_moa was not populated; the DrugBank record should be re-parsed to extract mechanism, categories, and toxicity fields
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.